Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.26) per share and revenue of $72.17 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Iovance Biotherapeutics Stock Up 3.0 %
Shares of IOVA stock traded up $0.17 on Friday, reaching $5.78. The company's stock had a trading volume of 10,884,741 shares, compared to its average volume of 8,530,247. The company has a market capitalization of $1.76 billion, a P/E ratio of -3.88 and a beta of 0.53. Iovance Biotherapeutics has a 12-month low of $5.05 and a 12-month high of $18.33. The stock's 50 day simple moving average is $6.48 and its 200-day simple moving average is $8.71.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on IOVA. HC Wainwright reiterated a "buy" rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. UBS Group initiated coverage on shares of Iovance Biotherapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $17.00 target price for the company. Finally, Piper Sandler decreased their price target on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a "neutral" rating on the stock in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $21.07.
Read Our Latest Stock Analysis on Iovance Biotherapeutics
About Iovance Biotherapeutics
(
Get Free Report)
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Featured Stories
Before you consider Iovance Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iovance Biotherapeutics wasn't on the list.
While Iovance Biotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
